We have compared the results of treatment with tamsulosin (0.4 mg once daily) in subgroups of patients with lower urinary tract symptoms suggestive of benign prostatic obstruction, based on two large-scale, open-label, observational studies. Improvements of IPSS or Q max were largely unaffected by patient age. Patients with severe symptoms bene®ted at least as much from treatment as those with mild or moderate symptoms, and the majority of patients with severe symptoms were shifted to the moderate or even mild symptoms group. We conclude that tamsulosin is effective in patients of all age groups, and should be considered as an alternative to surgery even in patients with severe symptoms.
Introduction
Benign prostatic hyperplasia is a disease state of high prevalence in elderly men. It is frequently associated with lower urinary tract symptoms (LUTS) and benign prostatic obstruction (BPO). 1 While surgery, particularly transurethral resection, has long been the mainstay of treatment for patients with LUTS suggestive of BPO, a large variety of treatment options have emerged in recent years. 2, 3 They include watchful waiting, minimally invasive surgical techniques and several types of medical treatment such as the 5a-reductase inhibitor, ®nasteride, 4, 5 and a 1 -adrenoceptor antagonists such as alfuzosin, doxazosin, tamsulosin and terazosin. 6, 7 When choosing the most appropriate treatment for a given patient, many physicians feel that watchful waiting is suf®cient for mild symptoms, medical therapy is appropriate for moderate symptoms, and that severe symptoms are best treated by surgery. While this approach is plausible, it is supported by only a few studies that have directly compared different forms of treatment. 8, 9 Since the treatment options for patients with LUTS suggestive of BPO differ in ef®cacy and qualitative and quantitative side effect pro®les, 2,3 it should be considered that a highly effective treatment may be acceptable to some patients despite frequent and/ or severe side effects, while less effective but better tolerated treatments may be more appropriate for others.
The scarcity of direct comparative studies between treatment forms may be related to the fact that direct comparisons, particularly of surgical vs medical treatments, are not easy to interpret. A complementary approach is the comparison of outcomes in subgroups of patients receiving the same treatment. This can test whether all subgroups of patients bene®t similarly. For example the treatment bene®t of ®nasteride is largely restricted to patients with prostates b 40 ml. 5 Although a 1 -blockers have become the preferred form of treatment for many urologists, 10 only limited data are available to compare their effectiveness in subgroups of patients with LUTS, 11, 12 and no such data are available for tamsulosin. Therefore, we have analysed the data from two observational studies with the a 1 -blocker tamsulosin, involving 19 365 patients, to compare treatment ef®cacy in subgroups of patients. An analysis of tolerability in subgroups of patients from this study has been published previously. 13 
Patients and methods
We have analysed the results of two open-label, observational studies on patients with LUTS suggestive of BPO which were performed as part of the post-marketing surveillance of tamsulosin in Germany. Therefore, no speci®c inclusion or exclusion criteria were required. Instead, the participating physicians were asked to document their observations in a standardized manner for patients who received tamsulosin prescriptions (0.4 mg once daily) according to the physician's medical judgement. Study 1 included 9507 patients (mean age 66.7 AE 0.1 y) and lasted four weeks, while study 2 included 9858 patients (mean age 65.1 AE 0.1 y) and lasted 12 weeks. Before and at the end of the observation period the International Prostate Symptom Score (IPSS), a free-¯ow maximum urine¯ow rate (Q max ) and the postvoiding residual urine were determined for objective assessment of symptomatology.
Data compilation was performed by Jung & Jung (Munich, Germany) and Innovex (Mannheim, Germany). Data are presented as means AE s.e.m. of n patients. Where alterations relative to baseline values are given, only those patients for whom completed case record forms were available before and after treatment were included. Statistical differences between groups were determined by t-tests or by analysis of variance followed by Tukey's multiple comparison test as indicated. A P`0.05 was considered statistically signi®cant.
Results
In a comparison of patients aged`61, 61±70 and b 70 y the pretreatment IPSS increased with age in both studies (Table  1) . However, the treatment-associated reduction of the IPSS was very similar in all three age groups with a mean reduction of $ 9 points corresponding to $ 50% ( Table 1) . The pretreatment Q max decreased with age in both studies (Table 1) . While the tamsulosin-induced absolute increases of Q max were slightly smaller in the oldest compared to the youngest age group (4.3 AE 0.2 vs 5.1 AE 0.2 ml/s and 4.3 AE 0.1 vs 4.8 AE 0.1 ml/s in studies 1 and 2, respectively; P`0.05), the relative increases of Q max were similar in all age groups, that is $ 40% (Table 1) .
To study treatment effects in relation to disease severity, patients were strati®ed according to their pretreatment IPSS (0±7, 8±19 and 20±35, Table 2 ), Q max (`10, 10± 15 and b 15 ml/s, Table 2 ) and post-voiding residual urine (`100 and ! 100 ml, Table 2 ). Patients with the most severe symptoms bene®ted at least as much from tamsulosin treatment as those with mild or moderate symptoms and, if anything, had even greater improvements (Table 2) . Even more importantly 42% and 50% of patients had an IPSS ! 20 and a Q max`1 0 ml/s prior to treatment, but only 5% and 15%, respectively, remained in that category after four weeks of tamsulosin treatment ( Figure 1 ). Among patients with ! 100 ml residual urine before treatment only 15% remained in that group after four weeks of treatment, while all others dropped tò 100 ml residual urine, and 41% of patients had values of`50 ml.
Discussion
The interpretation of the present study is limited by the facts that it did not include a placebo group, that it was International prostate symptom score and maximum urine¯ow rate before and after 4 (study 1) and 12 weeks (study 2) treatment with 0.4 mg tamsulosin once daily in relation to patient age. Data are mean AE s.e.m. of the indicated number of patients. done in an observational, open-label manner, and that it was short term (4±12 weeks). Therefore, this study was not intended to and should not be used to prove the effectiveness of tamsulosin treatment. However, the effectiveness of tamsulosin in the treatment for LUTS suggestive of BPO has already been documented in several placebo-controlled clinical trials. 14, 15 Indirect comparison with controlled clinical trials with other a 1 -blockers 6,7 and direct, double-blind comparisons with alfuzosin 16 and terazosin 17 show that tamsulosin has the same ef®cacy as other a 1 -blockers. Despite the absence of a placebo group the magnitude of IPSS and residual urine improvements in the present study is in good agreement with the results of placebo-controlled studies on tamsulosin. 14, 15 Some of our patients had only minimal symptoms, in other words, an IPSS 7 or a Q max ! 15 ml/s. However, this re¯ects one end of the spectrum of real life patients who seek treatment for LUTS, and all of our patients were judged to be candidates for tamsulosin treatment by a board-certi®ed urologist. Finally, the analysis of our data is justi®ed despite the short duration of treatment since the bene®t of tamsulosin treatment appeared almost completely in this time frame in the placebo-controled studies. 14, 15 Moreover, it has recently been reported from open-label extension studies of the placebo-controlled trials that the ef®cacy of tamsulosin treatment is maintained for at least three years. 18 Therefore, the present data may not allow conclusions regarding absolute bene®ts of tamsulosin treatment, but they are valid to compare treatment bene®t in patient subgroups. In this respect the large number of patients in the present study may allow a level of con®dence which is not feasible from smaller, placebo-controlled studies.
The effectiveness of an a 1 -blocker depends on the activity of the sympathetic nervous system on the one hand and on the postjunctional adrenoceptor responsiveness on the other. The activity of the human sympathetic nervous system increases in the elderly. 19±21 On the other hand, the postjunctional responsiveness to vascular a 1 -adrenergic stimulation 22, 23 and prostatic a 1 -adrenoceptor density 24 decrease with age. The net effect of increased sympathetic activity and decreased tissue responsiveness is dif®cult to predict. Since LUTS patients cover a wide age range, it is important to determine whether treatment options for LUTS are equally effective in all age groups. As expected we have observed that the severity of LUTS, as determined by IPSS and Q max , increased with age. However, the ability of tamsulosin to lower IPSS and to increase Q max was similar in all age groups, which is in agreement with considerably smaller studies with another a 1 -blocker, doxazosin.
12 Therefore, with regard to effectiveness, patients with LUTS suggestive of BPO of all ages may be candidates for treatment with tamsulosin and, perhaps, other a 1 -blockers.
In a given patient, subjective symptoms (as assessed by the IPSS), bladder outlet obstruction (as assessed by Q max ) or post-voiding residual urine with risk to develop infections of the lower urinary tract may be leading reasons to initiate treatment. The subjective symptoms are probably the main cause of treatment-seeking behaviour of patients. Placebo-controlled studies have demonstrated that a 1 -blockers in general 6, 7 and tamsulosin in particular 14, 15 improve all three categories of symptoms, that is, IPSS, Q max and residual urine. While it has been suggested that a-blocker treatment may improve symptoms but may leave some patients obstructed, a recent placebocontrolled study with tamsulosin in 193 patients has clearly demonstrated signi®cant improvements in pressure±¯ow parameters on tamsulosin relative to placebo treatment. 25 Whether this bene®t is maintained in longterm treatment remains to be studied. Our data show that patients with mild, moderate and severe symptoms pro®t similarly from tamsulosin treatment with regard to IPSS, Q max and residual urine. If anything, patients with more severe symptoms appear to bene®t even more than those with mild or moderate symptoms, but this may at least partly re¯ect the high baseline values. In this context it should be noted that patients with a higher baseline score require a larger absolute reduction in symptom scores to consider their improvement to be marked. 26 Therefore, it is a more important observation of our study that a major fraction of patients with severe symptoms prior to treatment have only mild symptoms following treatment.
Direct comparisons of tamsulosin with other a 1 -blockers 16, 17 and indirect comparisons based on numerous placebo-controlled studies for the individual drugs 6, 7 indicate that all a 1 -blockers are similarly effective in reducing IPSS and increasing Q max when given in International Prostate Symptom Score, maximum urine¯ow rate and post-voiding residual urine before and after 4 (study 1) and 12 weeks (study 2) treatment with 0.4 mg tamsulosin once daily in relation to baseline symptom severity. Data are mean AE s.e.m. of the indicated number of patients.
appropriate doses. Moreover, smaller studies with two other a 1 -blockers have reported ®ndings similar to those of the present study. 11, 12 Taken together, these ®ndings indicate that a 1 -blockers as a class are effective in all age groups of patients with LUTS suggestive of BPO. Their use should not be restricted to patients with moderate symptoms. Even patients with severe symptoms should be considered for a 1 -blocker treatment if no mandatory indication for surgery is present, for example, acute urinary retention. Whether an individual patient improves suf®ciently upon a 1 -blocker treatment to avoid surgery can be determined quickly since the bene®cial effects of a 1 -blockers in contrast to those of ®nasteride, 4 are already evident after a few weeks of treatment. 6, 7 In this respect an a 1 -blocker which does not require a titration phase at the beginning of treatment, such as tamsulosin, may have further bene®t since it allows an even faster decision as to whether surgery is necessary or can be avoided. Moreover, differences in tolerability between individual a 1 -blockers, which have been observed in direct 16, 17 and indirect comparisons, 6, 7 should be considered in the choice of treatment to maximize the overall bene®t/risk ratio.
